Next-gen Novo Nordisk shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
New results from weight-loss drug boost Novo’s stock value
New data from a study on Novo Nordisk’s weight-loss drug, amycretin, has shown positive results. Participants in the study who received the highest dose of the drug lost an average of 22 percent of their body weight after 36 weeks.
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American depositary receipt was down 38% in the six months prior to Friday’s announcement,
Trump’s plan to impose tariffs in bid to acquire Greenland could raise prices of Ozempic, Legos
President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to higher prices for popular weight-loss drugs Ozempic and Wegovy as well as Lego ...
Elon Musk admits to taking controversial weight loss drug previously opposed by RFK Jr.
Billionaire entrepreneur and top adviser to President-elect Donald Trump, Elon Musk, touted that he has reaped the benefits of Ozempic after fellow top Trump adviser, Robert F. Kennedy Jr., suggested ...
CNN18d
Trump’s quest for Greenland could make Ozempic even more expensive
President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, ...
News Medical2d
Dapagliflozin plus calorie restriction boosts remission rates in adults with type 2 diabetes and obesity
Findings indicate that dapagliflozin and calorie restriction together improve weight loss and metabolic health, increasing ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART ...
Science Daily6d
Diet and Weight Loss News
and choosing the optimal meals for weight loss can be challenging. A research team has developed a weight management program that helps individuals plan meals with the assistance of a web ...